BET-bromodomain and EZH2 inhibitor treated chronic GVHD mice have blunted germinal centers with distinct transcriptomes.
Sign Up to like & getrecommendations! Published in 2022 at "Blood"
DOI: 10.1182/blood.2021014557
Abstract: Despite advances in the field, chronic graft-vs-host-disease (cGVHD) remains a leading cause of morbidity and mortality following allogenic hematopoietic stem cell transplant. As treatment options remain limited, we tested efficacy of anti-cancer, chromatin modifying enzyme… read more here.
Keywords: ezh2 inhibitor; jq5; bet bromodomain; inhibitor ... See more keywords